NanoViricides Inc. (NNVC)

[crashco]

The potential to target cancer specific proteins with payload enhanced nanoviricides is certainly real. In that regard the article does present an additional line of business. (In fact it represents a return to the earliest days of TheraCour, therapeutic courier, when cell-specific transport of pharmaceutical payload was the primary vision.)
But the final sentence in paragraph 4 is most reassuring for NNVC’s current efforts. Reporting a critical characteristic of zero toxicity in Mega-dosage experimentation is fantastic. One of the next big milestones NNVC must achieve is to replicate these results in Human tests.